Literature DB >> 20535651

Oncogenic mutations of PIK3CA in human cancers.

Yardena Samuels1, Todd Waldman.   

Abstract

The involvement of the PIK3CA gene product p110α, the catalytic subunit of phosphatidylinositol 3-kinase (PI3K), in human cancer has been suggested for over 15 years, and support for this proposal had been provided by both genetic and functional studies, including most recently the discovery of common activating missense mutations of PIK3CA in a wide variety of common human tumor types. This chapter will focus on the discovery of these mutations and describes their relevance to a wide range of common human tumor types.Of note, the identification and functional analysis of the PIK3CA gene are reviewed in other chapters in this book. However, a brief mention will be made here of its general properties as background to our focus on the discovery of its cancer-specific mutations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20535651      PMCID: PMC3164550          DOI: 10.1007/82_2010_68

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  140 in total

1.  PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia.

Authors:  Monica Prasad Hayes; Hong Wang; Rosanny Espinal-Witter; Wayne Douglas; Garron J Solomon; Suzanne J Baker; Lora Hedrick Ellenson
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

2.  [Screening for mutations in the hotspot mutation regions of PIK3CA gene in nasopharyngeal carcinoma].

Authors:  Peng Liu; Da-Jiang Li; Hai-De Qin; Ru-Hua Zhang; Li-Zhen Chen; Yi-Xin Zeng
Journal:  Ai Zheng       Date:  2007-01

3.  Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.

Authors:  Naomi Maruyama; Yasuo Miyoshi; Tetsuya Taguchi; Yasuhiro Tamaki; Morito Monden; Shinzaburo Noguchi
Journal:  Clin Cancer Res       Date:  2007-01-03       Impact factor: 12.531

4.  Mutational analysis of beta-catenin and the RAS-RAF signalling pathway in early flat-type colorectal tumours.

Authors:  Masashi Mikami; Katsuhiko Nosho; Hiroyuki Yamamoto; Taiga Takahashi; Tadateru Maehata; Hiroaki Taniguchi; Yasushi Adachi; Akimichi Imamura; Masahiro Fujita; Masao Hosokawa; Fumio Itoh; Kohzoh Imai; Yasuhisa Shinomura
Journal:  Eur J Cancer       Date:  2006-09-29       Impact factor: 9.162

5.  Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.

Authors:  Jung-Sik Kim; Carolyn Lee; Challice L Bonifant; Habtom Ressom; Todd Waldman
Journal:  Mol Cell Biol       Date:  2006-10-23       Impact factor: 4.272

6.  PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.

Authors:  Ken-ichi Kozaki; Issei Imoto; Atiphan Pimkhaokham; Shogo Hasegawa; Hitoshi Tsuda; Ken Omura; Johji Inazawa
Journal:  Cancer Sci       Date:  2006-12       Impact factor: 6.716

7.  Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene.

Authors:  Claudia I Müller; Carl W Miller; Wolf-K Hofmann; Mitchell E Gross; Christine S Walsh; Norihiko Kawamata; Quang T Luong; H Phillip Koeffler
Journal:  Leuk Res       Date:  2006-06-09       Impact factor: 3.156

Review 8.  Epidermal growth factor receptor mutations in lung cancer.

Authors:  Sreenath V Sharma; Daphne W Bell; Jeffrey Settleman; Daniel A Haber
Journal:  Nat Rev Cancer       Date:  2007-03       Impact factor: 60.716

9.  PIK3CA alterations in primary (de novo) and secondary glioblastomas.

Authors:  Daisuke Kita; Yasuhiro Yonekawa; Michael Weller; Hiroko Ohgaki
Journal:  Acta Neuropathol       Date:  2007-01-18       Impact factor: 17.088

10.  Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.

Authors:  Lao H Saal; Peter Johansson; Karolina Holm; Sofia K Gruvberger-Saal; Qing-Bai She; Matthew Maurer; Susan Koujak; Adolfo A Ferrando; Per Malmström; Lorenzo Memeo; Jorma Isola; Pär-Ola Bendahl; Neal Rosen; Hanina Hibshoosh; Markus Ringnér; Ake Borg; Ramon Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-23       Impact factor: 11.205

View more
  95 in total

1.  New Mechanisms of mTOR Pathway Activation in KIT-mutant Malignant GISTs.

Authors:  Jerzy Lasota; Artur Kowalik; Anna Felisiak-Golabek; Sebastian Zięba; Zeng-Feng Wang; Markku Miettinen
Journal:  Appl Immunohistochem Mol Morphol       Date:  2019-01

Review 2.  High-throughput screening strategies for targeted identification of therapeutic compounds in colorectal cancer.

Authors:  Agnieszka B Bialkowska; Vincent W Yang
Journal:  Future Oncol       Date:  2012-03       Impact factor: 3.404

Review 3.  The pervasiveness of macropinocytosis in oncological malignancies.

Authors:  Cosimo Commisso
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-02-04       Impact factor: 6.237

Review 4.  Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications.

Authors:  Jiezhong Chen
Journal:  World J Virol       Date:  2012-12-12

5.  KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells.

Authors:  Dominic Leiser; Michaela Medová; Kei Mikami; Lluís Nisa; Deborah Stroka; Andree Blaukat; Friedhelm Bladt; Daniel M Aebersold; Yitzhak Zimmer
Journal:  Mol Oncol       Date:  2015-04-14       Impact factor: 6.603

6.  Editorial: cell movement.

Authors:  S Detchokul; A G Frauman
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

7.  PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex.

Authors:  Pengda Liu; Wenjian Gan; Y Rebecca Chin; Kohei Ogura; Jianping Guo; Jinfang Zhang; Bin Wang; John Blenis; Lewis C Cantley; Alex Toker; Bing Su; Wenyi Wei
Journal:  Cancer Discov       Date:  2015-08-20       Impact factor: 39.397

Review 8.  Toward rapamycin analog (rapalog)-based precision cancer therapy.

Authors:  Ling-hua Meng; X F Steven Zheng
Journal:  Acta Pharmacol Sin       Date:  2015-08-24       Impact factor: 6.150

9.  Driver gene mutations of non-small-cell lung cancer are rare in primary carcinoids of the lung: NGS study by ion Torrent.

Authors:  Gemma Armengol; Virinder Kaur Sarhadi; Mikko Rönty; Milja Tikkanen; Aija Knuuttila; Sakari Knuutila
Journal:  Lung       Date:  2015-02-14       Impact factor: 2.584

Review 10.  Nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation.

Authors:  Karen W Gripp; Laura Baker; Vinay Kandula; Katrina Conard; Mena Scavina; Joseph A Napoli; Gregory C Griffin; Mihir Thacker; Rachel G Knox; Graeme R Clark; Victoria E R Parker; Robert Semple; Ghayda Mirzaa; Kim M Keppler-Noreuil
Journal:  Am J Med Genet A       Date:  2016-05-18       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.